stars 1 stars 2 stars 3

IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IgM antibodies have inherent properties that we believe may enable them to bind more strongly to targets on the surface of cells than comparable IgG antibodies. We believe our proprietary IgM antibody technology platform is particularly well suited for developing T cell engagers, receptor cross-linking agonists, targeted cytokines, and target neutralizers. Our lead product candidate, Imvotamab, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, and it is currently in two Phase 2 clinical trials for the treatment of relapsed and/or refractory diffuse large B cell lymphoma and follicular lymphoma. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with relapsed and/or refractory solid and hematologic malignancies, and it is currently in a Phase 1 clinical trial. Also in our product pipeline is IGM-7354 and IGM-2644. IGM-7354 is an anti-PD-L1 IgM antibody that targets the delivery of interleukin-15 (IL-15) cytokines to the area of PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma.

View Top Employees from IGM Biosciences, Inc.
Ticker IGMS
Revenue $40.6 million
Funding $394.1 million
Employees 278 (278 on RocketReach)
Founded 2010
Address 325 E Middlefield Rd, Mountain View, California 94043, US
Phone (650) 965-7873
Industry Biotechnology, Business Services General, Business Services, Science and Engineering, Medical, Health Care, Therapeutics
Keywords Lymphoma Treatment, Hematologic Malignancies, Autoimmune Disease
Competitors Alector, Allakos Inc, AnaptysBio, Annexon Biosciences, Concert Pharmaceuticals, Inc.
SIC SIC Code 873 Companies, SIC Code 87 Companies
NAICS NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies

IGM Biosciences, Inc. Questions

The IGM Biosciences, Inc. annual revenue was $40.6 million in 2024.

Marvin Peterson is the Senior Vice President, Process Development and Manufacturing of IGM Biosciences, Inc..

278 people are employed at IGM Biosciences, Inc..

IGM Biosciences, Inc. is based in Mountain View, California.

The NAICS codes for IGM Biosciences, Inc. are [5417, 54, 541].

The SIC codes for IGM Biosciences, Inc. are [873, 87].

Top IGM Biosciences, Inc. Employees

View Similar People
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups / month.
Search over 700 million verified professionals across 35 million companies.
Get Contact Info
Get contact details including emails and phone numbers (business & personal).
High Performer Summer 2022 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2
G2Crowd Trusted
300K+ Plugin Users